Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
heat-killed cps
- Development stage
- Discontinued
- Lead developer
- Geisel School of Medicine at Dartmouth College
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intraperitoneal
01
Overview
Heat-killed cps is an inactivated preparation of the Toxoplasma gondii cps strain, which is a non-replicating uracil auxotroph created by deleting the carbamoyl phosphate synthetase II (CPS) gene. Developed at the Geisel School of Medicine at Dartmouth, this agent is primarily utilized in preclinical research as a negative control to investigate the mechanisms of parasite-based immunotherapy. While the live, invasion-competent cps strain triggers a robust Th1-dependent anti-tumor immune response involving IL-12 production, IFNγ secretion, and CD8+ T cell activation, the heat-killed version is unable to actively invade host cells. Consequently, it fails to elicit these protective immune mechanisms and does not provide a survival advantage in models of disseminated pancreatic cancer, demonstrating that active cellular invasion is a prerequisite for the strain's therapeutic efficacy.
- Other names
- heat-killed Toxoplasma gondii cps strainheat-killed uracil auxotroph Toxoplasma gondii
Beyond the preview
Go deeper on heat-killed cps.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on heat-killed cps.